INTEGRA LIFESCIENCES HLDGS
Reported by BNP Paribas Asset Management Holding S A
Reported 4,500,000 shares, unchanged from the prior quarter.
Reported value -5.9%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 4918000 |
| 2022-03-31 | 4721000 |
| 2022-06-30 | 4260000 |
| 2022-09-30 | 3935000 |
| 2022-12-31 | 4370000 |
| 2023-03-31 | 4361000 |
| 2023-06-30 | 4103000 |
| 2023-09-30 | 4110000 |
| 2023-12-31 | 4226000 |
| 2024-03-31 | 4311000 |
| 2024-06-30 | 2831000 |
| 2024-09-30 | 2851000 |
| 2024-12-31 | 2886000 |
| 2025-03-31 | 2947000 |
| 2025-06-30 | 2975000 |
| 2025-09-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2025 | Reduced | 0 | -3,000,000 (-100.0%) | 0 | $0 | 2025-11-07 | |
| Q2 2025 | Unchanged | 3,000,000 | 0 (0.0%) | < 0.01% | $2,975,000 | 2025-08-06 | |
| Q1 2025 | Unchanged | 3,000,000 | 0 (0.0%) | < 0.01% | $2,947,000 | 2025-05-14 | |
| Q4 2024 | Unchanged | 3,000,000 | 0 (0.0%) | < 0.01% | $2,886,000 | 2025-02-12 | |
| Q3 2024 | Unchanged | 3,000,000 | 0 (0.0%) | < 0.01% | $2,851,000 | 2024-11-08 | |
| Q2 2024 | Reduced | 3,000,000 | -1,500,000 (-33.3%) | < 0.01% | $2,831,000 | 2024-07-30 | |
| Q1 2024 | Unchanged | 4,500,000 | 0 (0.0%) | 0.01% | $4,311,000 | 2024-05-08 | |
| Q4 2023 | Unchanged | 4,500,000 | 0 (0.0%) | 0.01% | $4,226,000 | 2024-02-09 | |
| Q3 2023 | Unchanged | 4,500,000 | 0 (0.0%) | 0.01% | $4,110,000 | 2023-11-13 | |
| Q2 2023 | Unchanged | 4,500,000 | 0 (0.0%) | 0.01% | $4,103,000 | 2023-08-08 | |
| Q1 2023 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $4,361,000 | 2023-05-08 | |
| Q4 2022 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $4,370,000 | 2023-02-10 | |
| Q3 2022 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $3,935,000 | 2022-11-10 | |
| Q2 2022 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $4,260,000 | 2022-08-04 | |
| Q1 2022 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $4,721,000 | 2022-05-12 | |
| Q4 2021 | Unchanged | 4,500,000 | 0 (0.0%) | 0.02% | $4,918,000 | 2022-02-09 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
82 managers reported INTEGRA LIFESCIENCES HLDGS for Q2 2023.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Invesco Ltd | Unchanged | 58,000,000 | 0 | 0.01% | $52,954,000 | 10 qtrs |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | Added | 54,248,000 | +5,500,000 | 2.19% | $49,653,737 | 9 qtrs |
| Linden Advisors LP | New | 32,000,000 | +32,000,000 | 0.31% | $29,278,335 | 1 qtr |
| Citigroup Inc | Added | 26,602,000 | +1,975,000 | 0.02% | $24,287,626 | 10 qtrs |
| MACKAY SHIELDS LLC | Reduced | 26,274,000 | -221,000 | 0.67% | $24,083,322 | 10 qtrs |
| Aequim Alternative Investments LP | Reduced | 25,000,000 | -10,000,000 | 0.86% | $22,950,000 | 8 qtrs |
| AVIVA PLC | Unchanged | 24,625,000 | 0 | 0.09% | $22,453,518 | 9 qtrs |
| JPMorgan Chase & Co | Reduced | 23,134,000 | -254,000 | < 0.01% | $21,174,781 | 10 qtrs |
| CAPSTONE INVESTMENT ADVISORS LLC | Reduced | 22,000,000 | -5,000,000 | 0.1% | $20,196,000 | 10 qtrs |
| DLD Asset Management LP | Added | 17,711,000 | +1,535,000 | 1.77% | $16,255,571 | 4 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2023
- Filed
- August 08, 2023
- Filing type
- 13F-HR
- Position type
- NOTE 0.500% 8/1
Voting authority reported
- Sole
- 0
- Shared
- 61,083
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.